Related Experiment Video

Updated: Jun 20, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Relationship between preterm labor and thrombophilic gene polymorphism: A prospective sequential cohort study

Firdevs Uvuz1, Sevtap Kilic, Nafiye Yilmaz

  • 1Dr. Zekai Tahir Burak Women's Health and Research Hospital, Ankara, Turkey.

Gynecologic and Obstetric Investigation
|September 25, 2009
PubMed

Insights

This study found no link between common thrombophilic gene polymorphisms and premature birth in women without other risk factors. Further research is needed to understand the genetic causes of preterm labor.

Area of Science:

  • Genetics
  • Obstetrics
  • Perinatology

Background:

  • Preterm birth is a major global cause of infant mortality and morbidity.
  • While genetics and environment are implicated, data on genetic links to premature birth are scarce.

Purpose of the Study:

  • To investigate the association between specific thrombophilic gene polymorphisms and premature labor.
  • To compare the prevalence of these polymorphisms in women with unexplained preterm birth versus those with term birth.

Main Methods:

  • Compared 50 women with premature labor (no known risk factors) to 50 women with term labor.
  • Genotyped for methylenetetrahydrofolate reductase (MTHFR) C677T, MTHFR C1298T, prothrombin 20210A, factor V, and angiotensin-converting enzyme (ACE) polymorphisms.

Main Results:

  • No statistically significant differences were found in the frequencies of MTHFR C677T, MTHFR C1298T, prothrombin 20210A, factor V, or ACE polymorphisms between the premature and term labor groups.

Conclusions:

  • The studied thrombophilic gene polymorphisms are not associated with premature or term labor in this cohort.
  • The genetic underpinnings of unexplained preterm birth require further investigation beyond the tested polymorphisms.
Abstract

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...